Keeping An Early-Stage Cell Therapy Biotech In The Black With IN8bio's William Ho

Episode 311

0:00-55:13

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers up a candid and step-by-step look at what it takes to finance an early clinical-stage cell therapy company through a punishing IPO market and a long cash crunch. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.com Find Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Publisher

Business Of Biotech

Published

June 22, 2026

Duration

55 min

Format

Podcast

Category

Issues · Business

Source

RSS feed

Host

Ben Comer

BO

Business Of Biotech

@businessofbiotech

#keeping #stagecelltherapy #in8bioswilliamho #management #lifesciences

The Nile